Testing JWK001 Delivered Under the Retina for Wet Age-Related Macular Degeneration
Tests JWK001 given under the retina in people with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
Key facts
- Where
- Beijing, Chengdu, Chongqing, Harbin, Jilin City, Kunming, Nanjing, Shanghai, Shantou, Taiyuan, Tianjin, Wuhan, Zhejiang, and Zhengzhou, ChinaSee the 16 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07776522, who can take part
Where in China
- Beijing HospitalBeijing, ChinaTaking people
- Peking University People's HospitalBeijing, ChinaNot yet recruiting
- West China Hospital，Sichuan UniversityChengdu, ChinaTaking people
- Southwest Hospital, Army Medical University（Southwest Hospital）Chongqing, ChinaNot yet recruiting
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot yet recruiting
- The Second Hospital of Jilin UniversityJilin City, ChinaNot yet recruiting
- The First People's Hospital of Yunnan ProvinceKunming, ChinaNot yet recruiting
- Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaNot yet recruiting
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNot yet recruiting
- Shantou International Eye Center of Shantou University and The Chinese University of Hong KongShantou, ChinaNot yet recruiting
- Shanxi Bethune HospitalTaiyuan, ChinaNot yet recruiting
- Shanxi Eye HospitalTaiyuan, ChinaNot yet recruiting
- Tianjin Eye HospitalTianjin, ChinaNot yet recruiting
- General Hospital of Central Theater Command, Chinese People's Liberation ArmyWuhan, ChinaNot yet recruiting
- Zhejiang Provincial People's HospitalZhejiang, ChinaNot yet recruiting
- Henan Provincial People's HospitalZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- West China Hospital
- Trial code
- NCT07776522
- Record updated
- 20 August 2026
- Original description
This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.Read full original descriptionShow less
A Phase II Study to Evaluate the Safety and Preliminary Efficacy of Subretinal Administration of JWK001 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.
Inclusion: Written informed consent and ability to comply with the study protocol; Male or female, aged 50-85 years; Active subfoveal MNV secondary to nAMD requiring anti-VEGF treatment; Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center; Study-eye BCVA of 19-78 ETDRS letters; Pseudophakic study eye.
Exclusion: Intraocular surgery or intraocular corticosteroid treatment within 4 weeks at screening; Clinically significant systemic disease or infection, malignancy, prohibited concomitant treatment, prior gene therapy, or recent participation in another clinical trial; Any ocular condition other than nAMD that may affect vision, study assessments, treatment safety, or interpretation of results; Any ocular condition making the study eye unsuitable for subretinal injection; Active ocular infection or inflammation, or a history of idiopathic or autoimmune uveitis; Any other condition considered by the investigator to make the subject unsuitable for participation; Monocular status or non-study-eye BCVA <19 ETDRS letters.